Drug Trial Radar · NCT07119372
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
May 12, 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Aug 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.
Conditions
- Anemia
- Chronic Kidney Disease
- Chronic Kidney Disease Patients on Hemodialysis
- Chronic Kidney Disease 5D
Interventions
BCD-131 (pegdarbepoetin beta)Biological
BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 84 weeks
Mircera (methoxypolyethylene glycol-epoetin beta)Biological
Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks up to Week 48 inclusive; starting from Week 52, all subjects will be switched to BCD-131 treatment up to Week 84 inclusive.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)Time frame: During the assessment period at Weeks 28-32
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Limited Liability Company "Medical Center "NEFROS"
Krasnodar, Russia
Limited Liability Company Medical Center "NEPHROS"
Krasnodar, Russia
Limited Liability Company "Nephroline-Sibir"
Novosibirsk, Russia
State Autonomous Healthcare Institution Orenburg Regional Clinical Center of Surgery and Traumatology
Orenburg, Russia
"All-Russian Center for Emergency and Radiation Medicine named after A.M. Nikiforov" of the Ministry of Emergency Situations of the Russian Federation
Saint Petersburg, Russia
Limited Liability Company "Kupchinsky Outpatient Dialysis Center"
Saint Petersburg, Russia
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin
Saint Petersburg, Russia
Saint Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"
Saint Petersburg, Russia
Saint Petersburg State Budgetary Healthcare Institution "S.P. Botkin Clinical Infectious Diseases Hospital"
Saint Petersburg, Russia
St. Petersburg City Hospital No. 26
Saint Petersburg, Russia
State Budgetary Healthcare Institution "Volgograd Regional Uronephrological Center"
Volgograd, Russia
Limited Liability Company "Medical Diagnostic Center"
Yaroslavl, Russia
Limited Liability Company "FAMILY CLINIC"
Yekaterinburg, Russia
Sverdlovsk Regional Clinical Hospital No. 1
Yekaterinburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.